Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm

J Clin Oncol. 2010 Sep 20;28(27):e471-2; author reply e473. doi: 10.1200/JCO.2010.27.9984. Epub 2010 Jun 28.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Anthracyclines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Neoadjuvant Therapy
  • Patient Selection
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Anthracyclines
  • Taxoids